Fonar CEO testifies against proposed patent-law changes

Article

Damadian seeks protection for inventorsFonar CEO Dr. Raymond Damadian last week sat before the Houseof Representatives subcommittee that oversees U.S. patent lawto testify against several bills that he argues would give multinationalcorporations

Damadian seeks protection for inventors

Fonar CEO Dr. Raymond Damadian last week sat before the Houseof Representatives subcommittee that oversees U.S. patent lawto testify against several bills that he argues would give multinationalcorporations unfair advantages over independent inventors.

This attack, according to Damadian, began with the General Agreementon Tariffs and Trade, the sweeping international economic treatysigned in 1993. Legislation that carried GATT through Congressincluded an amendment that dropped a provision giving inventorspatent rights for a 17-year period following the receipt of apatent. In the place of that standard, patent holders were given20 years of protection commencing from the patent application'sfiling date.

As a witness before the House subcommittee on intellectual property,Damadian testified that the change allows adversaries of smallinventors to use legal maneuvering to delay the issuance of apatent while the clock ticks toward its expiration.

Damadian threw his support behind HR 539, authored by Rep. DanaRohrabacher (R-CA). It would set patent lifetimes at 17 yearsfrom the date of issuance or 20 years from the date of filing,whichever is longer. Damadian warned that protection for smallinventors would be gutted without the passage of HR 539.

Damadian also opposed several bills under consideration thathe said would favor multinational companies at the expense ofsmall inventors. Support for the reforms stems mainly from Japanesemultinationals and American companies, including IBM, 3M and CaterpillarTractor, Damadian said. The Republican majority in Congress isdivided in its support of the proposals.

"All together, this web of patent legislation is a carefullyorchestrated design to render the U.S. patent useless and destroywhatever potential it may have left to initiate competitive newbusiness enterprises and new employment for the people of America,"Damadian testified.

Damadian urged the subcommittee to reject the bills, warningthat their passage would be calamitous for the U.S. economy. Thesubject of the hearings hit especially close to home for Damadian,who has been locked in a struggle with GE Medical Systems relatingto MRI patents.

"These bills before Congress can only be construed as aconcerted attack on the entire U.S. patent system, the overallpurpose of which is to mortally wound it," he said.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.